In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Regeneron (REGN), with a price target of $575.00. The company’s shares closed last Monday at $547.52, close to its 52-week high of $574.33.
According to TipRanks.com, Newman is a 5-star analyst with an average return of 13.5% and a 43.8% success rate. Newman covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Hutchison China MediTech, and Atara Biotherapeutics.
Regeneron has an analyst consensus of Moderate Buy, with a price target consensus of $492.62, a -12.5% downside from current levels. In a report issued on April 17, Benchmark Co. also upgraded the stock to Buy with a $655.00 price target.
See today’s analyst top recommended stocks >>
Regeneron’s market cap is currently $60.24B and has a P/E ratio of 30.70. The company has a Price to Book ratio of 5.62.
Based on the recent corporate insider activity of 63 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of REGN in relation to earlier this year. Most recently, in February 2020, George Sing, a Director at REGN sold 2,500 shares for a total of $1,150,000.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.
Read More on REGN:
